Since p53 defects are detected in less than 10% of B-CLL patients at diagnosis [17,18], our study suggests that the anti-leukemic therapeutic potential of DCA, either used alone or in combination with Nutlin-3, is promising and should be further investigated since the majority of B-CLL are suitable to respond to the DCA+Nutlin-3 combination. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.